RESUMEN
Polyethylene terephthalate-based glitters (PET glitters) are a potential source of primary microplastics in the environment. However, the bioeffects of PET glitters and the associated leachates remain largely unknown. In this study, we investigated the individual and combined toxicity of five colors (silver, black, red, green, and blue) of PET glitters and their corresponding leachates on the cellular responses of Desmodesmus sp. The results indicated that the photosynthesis of Desmodesmus sp. could be partly affected by PET glitters through the shading effect, but not that of growth. Conversely, the leachates of red and green PET glitters significantly inhibited the growth of the microalga, suggesting a higher risk associated with additives leached from these colors of PET glitters. Furthermore, the adverse effects of the co-occurrence of PET glitters and leachates were closely related to oxidative stress responses in the microalgal cells, along with a color effect, which could be mainly attributed to variations in the composition and abundance of toxic additives in different colors of PET glitters. Overall, our findings provide insights into the ecological risks posed by glitters in aquatic environments and emphasize the importance of considering color factors in assessing microplastics toxicity.
Asunto(s)
Contaminantes Ambientales , Microalgas , Contaminantes Químicos del Agua , Microplásticos/toxicidad , Plásticos/toxicidad , Polietileno , Tereftalatos Polietilenos/toxicidad , Contaminantes Químicos del Agua/toxicidad , Contaminantes Químicos del Agua/análisisRESUMEN
BACKGROUND: Knee osteoarthritis (OA) is a prevalent disabling disorder that involves changes in articular cartilage damage, subchondral bone remodeling, synovitis, and abnormal infrapatellar fat pad (IPFP). Due to the complicated etiology and numerous phenotypes of knee OA, limited improvement is achieved for treatments among knee OA patients with different phenotypes. Inflammatory OA phenotype is a typical knee OA phenotype, and individualized treatment targeting inflammation is a promising way to obtain an optimal therapeutic effect for people with inflammatory knee OA phenotype. Glucocorticoid is a traditional anti-inflammatory drug for knee OA, and intra-articular glucocorticoid injections are recommended clinically. However, emerging evidence has shown that repeated intra-articular glucocorticoid injections in the long term would induce cartilage loss. IPFP and its adjacent synovium are considered as the main source of inflammation in knee OA. This GLITTERS trial aims to investigate if a glucocorticoid injection into the IPFP is effective and safe over 12 weeks among knee OA patients with an inflammatory phenotype. METHODS: GLITTERS is a multicenter, double-blinded, randomized, and placebo-controlled clinical trial among knee OA patients with both Hoffa-synovitis and effusion-synovitis. Sixty participants will be allocated randomly and equally to either the glucocorticoid group or the control group. Each group will receive an injection of glucocorticoid or saline into the IPFP with an intra-articular hyaluronic acid injection as a background treatment at baseline and be followed at 4, 8, and 12 weeks. The primary outcomes will be changes in knee pain on a visual analog scale and effusion-synovitis volume measured on magnetic resonance imaging (MRI). The secondary outcomes will be changes in the total score of Western Ontario and McMaster Universities Osteoarthritis Index score, MRI-detected Hoffa-synovitis score, quality of life, pain medication use, IPFP volume, and the incidence of adverse reactions. Data analyses based on the intention-to-treat principle will include mixed-effects regressions, Wilcoxon rank-sum tests, and chi-square tests (or Fisher's exact test). DISCUSSION: GLITTERS may provide high-quality evidence for the efficacy and safety of ultrasound-guided glucocorticoid injections into IPFP among people with inflammatory knee OA in a short term. The results of this trial are expected to provide a reliable reference for a longer-term risk-benefit profile of this treatment in the future. TRIAL REGISTRATION: ClinicalTrials.gov NCT05291650. Registered on 23 March 2022.
Asunto(s)
Osteoartritis de la Rodilla , Sinovitis , Humanos , Osteoartritis de la Rodilla/terapia , Glucocorticoides/efectos adversos , Calidad de Vida , Dolor/tratamiento farmacológico , Inyecciones Intraarticulares , Sinovitis/diagnóstico por imagen , Sinovitis/tratamiento farmacológico , Sinovitis/complicaciones , Inflamación/tratamiento farmacológico , Tejido Adiposo , Resultado del Tratamiento , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Multicéntricos como AsuntoRESUMEN
The awareness of impact of microplastics has led stakeholders to define strategies for the reduction of plastic emission and for their removal from aquatic environments. Glitter includes a wide range of shapes, chemical types of plastics covered by a metallic layer and color addition that confer them the typical 'sparkling' aspect. Here we focus on critical aspects that make glitter a product with a potential of significant environmental impact suggesting the need to take effective measures to limit emissions. Glitter is used here as a paradigm for all emergent plastic pollutants which calls for a deeper rethinking of our concept of sustainability. We are only at the beginning of the studies on glitter in the aquatic environment but on the basis of their potential impacts now is the time to take decisions taking the sparkle off the sparkling time.